Trial Profile
A phase 1 trial of AP-002 for cancer-induced skeletal related events
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs AP-002 (Primary)
- Indications Bone cancer; Bone disorders; Malignant hypercalcaemia; Osteoporosis
- Focus Adverse reactions
- 11 May 2018 Altum pharmaceuticals is planning to initiate this trial in Q1 2019.
- 11 May 2018 New trial record